Health tech company building a diagnostics-as-a-service platform for population-scale early detection of chronic diseases, with a focus on cardio-renal-metabolic conditions.
We combine at-home and point-of-care testing, sample logistics, and AI-assisted clinical reporting into a single end-to-end solution — making it easy for pharma companies, hospitals, and health systems to deploy large-scale screening programs without operational burden.
For pharma partners, we offer a ready-to-deploy infrastructure to run real-world screening campaigns, generate patient data, identify at-risk populations, and support recruitment for clinical programs. Our platform covers the full screening journey: kit activation, guided sample collection, certified lab analysis, and results delivery with medical interpretation.
Founded in Madrid in 2021, Ailin Health has run screening programs across Europe in partnership with leading pharma companies, patient associations, and clinical institutions. We are CE-marked and fully compliant with EU MDR and GDPR regulations.
Our mission: shift healthcare from reactive treatment to proactive prevention — earlier, at scale, and closer to the patient.
Sector
Business Development
Ailin Health
Service
Out-of-clinic population screening programmes for pharma, public health and insurers
Ailin runs out-of-clinic screening programmes end to end: population targeting, at-home sampling, accredited-lab analysis and medically validated results. We help partners find at-risk patients earlier, at scale, and generate real-world evidence.
Business Development at Ailin Health
Madrid, Spain
Partnership
Ailin is expanding its out-of-clinic screening delivery network across Europe. We are looking for accredited clinical laboratories, sample-logistics providers and CROs to support decentralised screening and study-recruitment programmes in new markets.
Business Development at Ailin Health
Madrid, Spain